Advokatfirman Lindahl advises NeuroVive Pharmaceutical AB (publ), listed on Nasdaq Stockholm, in connection with its directed share issue. The share issue has been directed to a limited group of institutional qualified investors in the US through a private placement. The share volume and price per share have been determined through an accelerated bookbuilding process, where NeuroVive also has retained Chardan Capital Markets, LLC (US) as Lead Placement Agent and Sole Bookrunner, J. Streicher Capital, LLC (US) as Joint Lead Manager and HDR Partners AB as financial advisor. In total, NeuroVive has raised MSEK 70 through the issue before transaction costs.
A prospectus for the admission to trading of the shares issued in the new share issue is expected to be announced around 18 May 2015.
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases.
Advokatfirman Lindahl assists NeuroVive in the transaction through Annika Andersson (Capital Markets and Public M&A) with the assistance of Maria Arnoldsson (project manager, Capital Markets and Public M&A), Gabriela Baier-Sandén and Sebastian Iso-Kamula (Capital Markets and public M&A), Jonas Löfgren (Life Science), Annie Kabala (Life Science/Intellectual Property) and Anna Romell Stenmark (Tax).
